Jeff Madwed is Executive Director of the JuvTherapeutics Division at Juvenescence, where he is currently leading Souvien Therapeutics, a company creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic mechanisms, and Selah Therapeutics, a company developing novel ketone-based therapies for the treatment of age-related diseases such as heart failure, chronic kidney disease, migraine, epilepsy and others.

Jeff is a pharmacologist, research project leader and translational researcher. Jeff joined Juvenescence in July 2020, after roles at Boehringer Ingelheim Pharmaceutics in Ridgefield, CT, Merck in Rahway/Kenilworth, NJ and Mitsubishi-Tanabe in Jersey City, NJ, where he played a major pre-clinical pharmacology role in the development of Flomax (tamsulosin) and Micardis (telmisartan).

Jeff completed his Ph.D. at Harvard University in Physiology and Biophysics. He proceeded to carry out post-doctoral work at the St. Luke’s Hospital/Kansas University Medical School in Kansas City, MO, and then at Physio-Control/University of Washington in Seattle before beginning his pharmaceutical career.